Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 40

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 40
---
 repriced on May 21, 2024, as described above. The exercise price of the repriced option, after giving effect to the option repricing, is reflected in the table above and assumes achievement of the Retention Period End Date. If the option is exercised prior to the Retention Period End Date, the exercise price would be: $9.66 for the option with a vesting start date of January 1, 2022; $4.25 for the option with a vesting start date of January 1, 2023; and $6.09 for the option with a vesting start date of January 1, 2024. For more information, see “Repricing of Designated Underwater Stock Options” above.

#### Executive Compensation Arrangements

#### Employment agreements

#### Dr. Zeskind
We entered into an employment agreement with Dr. Zeskind on July 23, 2021, pursuant to which we employ Dr. Zeskind as our President and Chief Executive Officer. The employment agreement has an indefinite term.

<div align='center'>27</div>

TABLE OF CONTENTS

The employment agreement provides for an initial annual base salary of $551,000, which was most recently increased to $641,493 effective January 1, 2025, and for a target annual performance bonus equal to 50% of Dr. Zeskind’s annual base salary to be based on the attainment of performance objectives determined by our Board of Directors.

If we terminate Dr. Zeskind’s employment without “cause”, or he resigns for “good reason” other than in connection with a change in control of the Company, subject to his execution and non-revocation of a separation agreement and release in favor of our Company and compliance with restrictive covenants contained therein, Dr. Zeskind will be entitled to receive the following termination payments: (i) his continued payment of base salary for twelve months, (ii) any unpaid bonus earned for the year prior to the year of termination, and (iii) direct payment of or reimbursement for COBRA premiums, less the amount Dr. Zeskind would have paid for coverage as an active employee, for up to 12 months. If such a qualifying termination occurs on or within 12 months following the date of a change in control of the Company or during the 3-month period prior to the date of a change in control of the Company, subject to his execution and non-revocation of a